B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy.

Jennifer A Woyach Paolo Ghia John C Byrd Inhye E Ahn Carol Moreno Susan M O'Brien Daniel M Jones Leo W K Cheung Elizabeth Chong Kevin Kwei James P Dean Danelle F James Adrian Wiestner

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

This systematic investigation describes development of mutations over time in patients without PD and informs the potential clinical opportunity to optimize ongoing benefits for such patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic lymphocytic leukemia
ejection fraction
chronic kidney disease
peritoneal dialysis
bone marrow
mesenchymal stem cells
risk assessment